NCT06225570

Weekly Isotretinoin vs Tetracycline for Moderate Acne

Randomized Controlled Trial of Weekly Oral Isotretinoin vs. Oral Tetracyclines for the Treatment of Moderate Acne Vulgaris
Medical University of South Carolina·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Acne Vulgaris
Drug/Device/Intervention
Isotretinoin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Medical University of South Carolina
Timeline & enrollment
Phase
Phase 1
Start date
Feb 01, 2024
End date
Jun 01, 2025
Enrollment
50 participants
Primary outcome

Efficacy using Comprehensive Acne Severity Scale

Summary

In the effort to find better treatments for Moderate Acne, which often relies on long-term
 antibiotic use, researchers are exploring alternative options. While Isotretinoin, a Vitamin
 A derivative, is highly effective for severe acne, its side effects limit its use for milder
 cases. A recent study from our institution investigated a new approach: weekly Isotretinoin
 dosing. The results were promising, with acne improvement and no major side effects. This
 suggests that weekly Isotretinoin could be a successful alternative for moderate acne in both
 males and females. To validate these findings, investigators propose a randomized controlled
 trial comparing weekly Isotretinoin to daily Doxycycline over four months. This study could
 confirm the safety and effectiveness of weekly Isotretinoin, as well as shed light on patient
 satisfaction, and long-term results compared to standard antibiotics. This research may offer
 a breakthrough in treating moderate acne while addressing concerns about antibiotic overuse.

ICD-10 classifications
Acne vulgarisAcneAcne, unspecifiedAcné excoriéeOther acne
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06225570
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06225570 through Pure Global AI's free database. This Phase 1 trial is sponsored by Medical University of South Carolina and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.